Insight Pharma Newsletter

Dear Reader :

This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, covers an eclectic mix of stories including what to expect in the world of biotech financing and the upcoming spin-off of Sandoz.

We tell you why biotech investors are becoming more careful about where they park their money while Sandoz CEO Richard Saynor talks about how he expects to keep the business ‘driving’, amid the upcoming separation from parent company Novartis.

There’s also an interesting piece on whether CAR-NK cell therapies could potentially outshine traditional CAR-Ts for the treatment of some cancers.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA

Perspective from Industry Leaders


Rest In Peace SPACs And Pseudo-Platforms: What Lies Ahead For Biotechs Going Public In 2023	Sandoz CEO Saynor Talks Spinoff, Leadership And Place Among Peers
Panelists at the BIO CEO and Investor Conference foresee some changes coming as biotech investors become more judicious about where...	In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation....

LICENSING & COLLABORATION AGREEMENTS


Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing	Capitainer Positions Its qDBS Technology As Catch-All Blood Testing Solution With AstraZeneca
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes...	The Swedish company has tweaked its dried blood spot sampling technology so that it can produce quantitative results with samples processed....

NEXT GEN: R&D


The Cancer Cell Therapy Showdown: CAR-Ts Versus CAR-NKs	US FDA Eyes Project Orbis-Type Approach For Cell And Gene Therapies
Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs....	A process in which the FDA coordinates reviews with other regulators would allow for better leveraging of global patient populations with ultra-rare...

CLINICAL TRIALS


Decentralized Clinical Trials ‘No Longer A Leap Of Faith’	Experts Want To Drop Confusing Terminology For Decentralized Clinical Trials
This second segment of a two-part Pink Sheet article on decentralized clinical trials looks at ensuring that staff at study sites are on onboard...	A new scientific paper drawn up by experts on behalf of the EU public-private Trials@Home project discusses the pros and cons of various...

Citeline Contact

Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India

Mobile: +91 994 5273146
Email: poornachandra.tejasvi@informa.com

Client Services: clientservices@pharmaintel.informa.com

IPA Contact

Direct: +91 022 2610 9281
Email: info@ipa-india.org